Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA; CATIE investigators..

Br J Psychiatry. 2008 Jul;193(1):37-43. doi: 10.1192/bjp.bp.107.042630.

2.

Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial.

Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA.

Schizophr Res. 2010 Feb;116(2-3):118-25. doi: 10.1016/j.schres.2009.09.026.

PMID:
19864114
3.

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA.

J Clin Psychiatry. 2011 Jan;72(1):75-80. doi: 10.4088/JCP.09m05258gre.

4.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators..

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
5.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194
6.

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

Schizophr Res. 2011 Dec;133(1-3):42-6. doi: 10.1016/j.schres.2011.09.018.

PMID:
22000938
7.

Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.

Gharabawi GM, Greenspan A, Rupnow MF, Kosik-Gonzalez C, Bossie CA, Zhu Y, Kalali AH, Awad AG.

BMC Psychiatry. 2006 Oct 20;6:45.

8.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Review.

PMID:
23055416
9.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators..

N Engl J Med. 2005 Sep 22;353(12):1209-23. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

10.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

11.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators.; Neurocognitive Working Group..

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
12.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators..

Am J Psychiatry. 2006 Dec;163(12):2080-9.

PMID:
17151158
14.

Effectiveness of switching antipsychotic medications.

Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA.

Am J Psychiatry. 2006 Dec;163(12):2090-5.

PMID:
17151159
15.

What CATIE found: results from the schizophrenia trial.

Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA.

Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/appi.ps.59.5.500.

16.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
17.

Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.

Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G.

Eur Neuropsychopharmacol. 2014 Jul;24(7):1078-85. doi: 10.1016/j.euroneuro.2014.03.001.

PMID:
24726579
18.

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; CATIE Investigators..

Schizophr Res. 2008 Mar;100(1-3):39-52. doi: 10.1016/j.schres.2007.11.034.

PMID:
18191383
19.

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW.

J Clin Psychiatry. 2006 Mar;67(3):453-60.

PMID:
16649833
20.
Items per page

Supplemental Content

Support Center